Document Detail


Omalizumab is effective in the long-term control of severe allergic asthma.
MedLine Citation:
PMID:  12952109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Previous reports show that addition of omalizumab to standard therapy reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids (ICSs) and rescue medication in patients with allergic asthma.
OBJECTIVE: To determine the effect of omalizumab on long-term disease control in patients with severe allergic asthma.
METHODS: The present study concerns the 24-week, double-blind extension phase to a previous 28-week core study in which patients received subcutaneous omalizumab or matching placebo (at least 0.016 mg/kg/IgE [IU/mL] every 4 weeks) for 16 weeks in addition to their existing ICS therapy (beclomethasone dipropionate [BDP]; steroid-stable phase), followed by a 12-week phase in which controlled attempts were made to gradually reduce ICS therapy (steroid-reduction phase). During the extension phase patients were maintained on randomized treatment (omalizumab or placebo) and the lowest sustainable dose of BDP. The use of other asthma medications was permitted during the extension phase. Investigators were also allowed to switch patients from BDP to other ICS medications if considered necessary.
RESULTS: A total of 460 patients (omalizumab, n = 245; placebo, n = 215) entered the extension phase. Overall, omalizumab-treated patients experienced significantly fewer exacerbations vs placebo during the extension phase (0.60 and 0.83 exacerbations per patient, respectively; P = 0.023), despite a sustained significant reduction in their use of ICS (mean BDP equivalent dose: omalizumab, 227 microg/d; placebo, 335 microg/d; P < 0.001). Treatment with omalizumab was well tolerated and the incidence of adverse events was similar in both treatment groups.
CONCLUSIONS: These results indicate that omalizumab is effective in the long-term control of severe allergic asthma.
Authors:
Bobby Quentin Lanier; Jonathan Corren; William Lumry; Jeen Liu; Angel Fowler-Taylor; Niroo Gupta
Related Documents :
17460439 - Treatment for churg-strauss syndrome: induction of remission and efficacy of intravenou...
19845819 - Basic measures and systemic medical treatment of patients with toxic epidermal necrolysis.
20964369 - Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses.
20406589 - Olea sublingual allergoid immunotherapy administered with two different treatment regim...
11075769 - High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial.
8889459 - Oral ph-modified release budesonide versus 6-methylprednisolone in active crohn's disea...
24720139 - Results of modified dufourmentel rhomboid flap in patients with extensive sacrococcygea...
23456099 - One-year results of reduced fluence photodynamic therapy for central serous chorioretin...
3884019 - Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and nor...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  91     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-09-03     Completed Date:  2003-09-30     Revised Date:  2013-01-18    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  154-9     Citation Subset:  IM    
Affiliation:
Lanier Education and Research Network, Fort Worth, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intranasal
Adolescent
Adult
Aged
Anti-Asthmatic Agents / administration & dosage*
Anti-Inflammatory Agents / administration & dosage
Antibodies, Anti-Idiotypic / administration & dosage*
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Beclomethasone / administration & dosage
Child
Double-Blind Method
Drug Therapy, Combination
Female
Forced Expiratory Volume / drug effects,  immunology
Glucocorticoids / administration & dosage
Humans
Injections, Subcutaneous
Longitudinal Studies
Male
Middle Aged
Status Asthmaticus / drug therapy,  immunology,  prevention & control*
Chemical
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Anti-Inflammatory Agents; 0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Glucocorticoids; 0/anti-IgE antibodies; 0/omalizumab; 4419-39-0/Beclomethasone
Comments/Corrections
Comment In:
Ann Allergy Asthma Immunol. 2003 Aug;91(2):117-8   [PMID:  12952102 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinically important differences in health-related quality of life for patients with asthma: an expe...
Next Document:  Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic...